Physician profile
Daniel A Orlando
NPI 1043291982
$4,134.91
in general payments reported to CMS, 2019-2025
41 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $299 · 2021: $200 · 2022: $234 · 2023: $511 · 2024: $928 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369 · Education: $75.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.55 |
| Education | $75.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $818.33 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $477.23 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.10 | 2019-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $270.98 | 2020-2025 | Wakix |
| Inari Medical, INC. | $190.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insmed, INC. | $189.79 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $170.80 | 2023-2025 | Tyvaso, Orenitram, Remodulin |
| Amgen INC. | $167.18 | 2023-2025 | Tezspire |
| Philips North America LLC | $129.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $121.97 | 2020-2025 | Winrevair, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $113.53 | 2019-2025 | |
| Abbvie INC. | $106.46 | 2025 | |
| Jazz Pharmaceuticals INC. | $100.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.55 | 2023-2025 | Dupixent |
| Vapotherm INC | $84.44 | 2022-2023 | Vapotherm |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Orlando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.